ContraFect’s Path Forward Gets Murky With Exebacase Trial Failure
The company said it would discontinue the Phase III trial of the MRSA drug for futility, leaving it with no major catalysts and an uncertain cash position.
The company said it would discontinue the Phase III trial of the MRSA drug for futility, leaving it with no major catalysts and an uncertain cash position.